Artelo biosciences announces selection of aptus clinical ltd. as clinical research organization for phase 1b/2a study of art27.13

Artelo biosciences, inc. announced that it has selected aptus clinical ltd. (aptus), a specialist clinical contract research organization based in the united kingdom (uk) with particular expertise in oncology, rare diseases and advanced therapies, as its contract research organization (cro) for the company's planned phase 1b/2a randomized, placebo-controlled trial of art27.13, its synthetic cannabinoid for the treatment of anorexia and weight loss associated with cancer. this latest agreement builds on earlier collaborations between artelo and aptus, which included feasibility studies, protocol design, and clinical site identification and selection. the art27.13 program will continue to be under the operational stewardship of artelo's uk subsidiary at the alderley park biohub in cheshire. art27.13 is a highly potent peripherally selective synthetic dual cannabinoid agonist believed to target peripheral cannabinoid receptors sending a feeding message to the brain. the combined phase 1b/2a trial is expected to enroll up to 49 subjects at clinical sites within the uk. the study is designed to determine the most effective and well tolerated dose in cancer patients and evaluate activity using criteria such as weight gain, lean body mass, and improvement of anorexia.
ARTL Ratings Summary
ARTL Quant Ranking